BRPI0520000A2 - composição compreendendo acetaminofeno, cafeìna e opcionalmente aspirina juntos com um agente alcalino para absorção intensificada - Google Patents

composição compreendendo acetaminofeno, cafeìna e opcionalmente aspirina juntos com um agente alcalino para absorção intensificada

Info

Publication number
BRPI0520000A2
BRPI0520000A2 BRPI0520000-8A BRPI0520000A BRPI0520000A2 BR PI0520000 A2 BRPI0520000 A2 BR PI0520000A2 BR PI0520000 A BRPI0520000 A BR PI0520000A BR PI0520000 A2 BRPI0520000 A2 BR PI0520000A2
Authority
BR
Brazil
Prior art keywords
composition
caffeine
alkaline agent
acetaminophen
antipyretic
Prior art date
Application number
BRPI0520000-8A
Other languages
English (en)
Inventor
Rong Liu
Michael Corbo
Jatin Desai
Gerard P Frunzi
Xiaohong Qi
Candice Y Choi
Rahul R Gandhi
Atef Z Boulos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0520000A2 publication Critical patent/BRPI0520000A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO COMPREENDENDO ACETAMINOFENO, CAFEìNA E OPCIONALMENTE ASPIRINA JUNTOS COM UM AGENTE ALCALINO PARA ABSORçãO INTENSIFICADA. A presente invenção refere-se a um princípio de atividade de uma primeira composição analgésica/antipirética contendo uma quantidade analgésica/antipirética eficaz de acetaminofeno, cafeína e, opcionalmente, aspirina é encurtado incorporando na primeira composição um princípio de quantidade de encurtamento da atividade analgésica/antipirética de pelo menos um agente alcalino por meio do qual uma segunda composição é produzida. A segunda composição sendo bioequivalente à primeira composição mas tendo um princípio mais curto de atividade analgésica/antipirética do que o da primeira composição.
BRPI0520000-8A 2004-10-28 2005-10-26 composição compreendendo acetaminofeno, cafeìna e opcionalmente aspirina juntos com um agente alcalino para absorção intensificada BRPI0520000A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62281204P 2004-10-28 2004-10-28
PCT/US2005/038507 WO2006049978A1 (en) 2004-10-28 2005-10-26 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkiline agent fr enhanced absorption

Publications (1)

Publication Number Publication Date
BRPI0520000A2 true BRPI0520000A2 (pt) 2009-04-07

Family

ID=35744599

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520000-8A BRPI0520000A2 (pt) 2004-10-28 2005-10-26 composição compreendendo acetaminofeno, cafeìna e opcionalmente aspirina juntos com um agente alcalino para absorção intensificada

Country Status (17)

Country Link
US (1) US20070298096A1 (pt)
EP (1) EP1807068B1 (pt)
JP (1) JP2008518914A (pt)
CN (1) CN101048155A (pt)
AR (1) AR051145A1 (pt)
AT (1) ATE460930T1 (pt)
AU (1) AU2005302618B2 (pt)
BR (1) BRPI0520000A2 (pt)
CA (1) CA2583517C (pt)
DE (1) DE602005020048D1 (pt)
MX (1) MX2007005121A (pt)
NO (1) NO20072255L (pt)
PE (1) PE20061125A1 (pt)
PL (1) PL1807068T3 (pt)
PT (1) PT1807068E (pt)
RU (1) RU2398571C2 (pt)
WO (1) WO2006049978A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607085D0 (en) * 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
CN100417385C (zh) * 2006-09-26 2008-09-10 林星 一种用于治疗外伤的外用制剂
GB0707489D0 (en) * 2007-04-18 2007-05-23 Renaissance Pharma Compounds
CN101596163B (zh) * 2008-06-06 2012-06-27 康美保宁（四川）制药有限公司 阿咖酚微丸制剂及其制备方法
GB0813929D0 (en) 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
CN102861040B (zh) * 2012-08-02 2014-04-23 广东环球制药有限公司 含有阿司匹林、对乙酰氨基酚和咖啡因的药物组合物及其制备方法
CN102949401A (zh) * 2012-09-06 2013-03-06 广东九明制药有限公司 对乙酰氨基酚、乙酰水杨酸和咖啡因组合物及其制备工艺
US10124005B1 (en) * 2017-12-15 2018-11-13 Lisa Josette Myslinski Multisymptom migraine combination medication
CN110711197B (zh) * 2018-07-12 2023-11-24 北京恒润泰生医药科技有限公司 阿司匹林和对乙酰氨基酚的分子复合物加咖啡因,其制备,活性及应用
CN108853124A (zh) * 2018-08-15 2018-11-23 康美保宁（四川）制药有限公司 一种阿咖酚制剂及其制剂方法
GB202007670D0 (en) * 2020-05-22 2020-07-08 Glaxosmithkline Consumer Healthcare Holdings Us Llc Pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
CA1182049A (en) * 1981-07-13 1985-02-05 Francis J. Sterbenz Apap antacid composition
US5296241A (en) * 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
JP3122748B2 (ja) * 1991-11-29 2001-01-09 ライオン株式会社 イブプロフェン含有解熱鎮痛剤
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
JPH06227995A (ja) * 1993-02-03 1994-08-16 Takeda Chem Ind Ltd 安定化された固型製剤
JPH07206689A (ja) * 1994-01-21 1995-08-08 Barnett Lab Ltd 治療組成物および宿酔の治療のためのこの組成物の使用法
DE19502789A1 (de) * 1995-01-28 1996-08-01 Dirk Krischenowski Arzneimittel
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
US5972916A (en) * 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
JP2002012557A (ja) * 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
KR20040004638A (ko) * 2001-05-25 2004-01-13 에스에스 세야쿠 가부시키 가이샤 의약 조성물
JP4553552B2 (ja) * 2003-01-08 2010-09-29 日東薬品工業株式会社 生体リズム応用キット

Also Published As

Publication number Publication date
CA2583517C (en) 2013-06-04
PL1807068T3 (pl) 2010-08-31
EP1807068A1 (en) 2007-07-18
PT1807068E (pt) 2010-04-19
US20070298096A1 (en) 2007-12-27
PE20061125A1 (es) 2006-11-08
RU2007119641A (ru) 2008-12-10
EP1807068B1 (en) 2010-03-17
AR051145A1 (es) 2006-12-20
RU2398571C2 (ru) 2010-09-10
AU2005302618B2 (en) 2009-10-22
NO20072255L (no) 2007-07-18
CN101048155A (zh) 2007-10-03
ATE460930T1 (de) 2010-04-15
DE602005020048D1 (de) 2010-04-29
JP2008518914A (ja) 2008-06-05
AU2005302618A1 (en) 2006-05-11
WO2006049978A1 (en) 2006-05-11
CA2583517A1 (en) 2006-05-11
MX2007005121A (es) 2007-06-22

Similar Documents

Publication Publication Date Title
BRPI0520000A2 (pt) composição compreendendo acetaminofeno, cafeìna e opcionalmente aspirina juntos com um agente alcalino para absorção intensificada
Corbett Resolution rules: agreement in person, number, and gender
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
BRPI0513847A (pt) formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
BRPI0809883B8 (pt) produto absorvente para prevenção de vazamento
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
BR0207726A (pt) Sais farmacêuticos
BR0204001A (pt) Forma de dosagem oral sólida de simeticona
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
BRPI0620863A8 (pt) comprimido em camadas com combinação de liberação tripla
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
UY28509A1 (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
BRPI0010891A (pt) geração de microespuma terapêutica.
BRPI0114927B8 (pt) composição de gel farmacêutica não aquosa para aplicação na pele, e, uso de uma composição
BR0013826A (pt) Formas orais de apresentação
AR024228A1 (es) Una composicion farmaceutica que comprende un sensibilizador de insulina y otro agente antidiabetico
BRPI0409945A (pt) forma de dosagem resistente à alteração
BR112012029812A2 (pt) composição cosmética à base de um polímero supramolecular e uma carga absorvente
CO5150236A1 (es) Metodo para tratar asma inducida por el ejercicio inducida por el ejercicio
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
BRPI0514474A (pt) multiparticulados
BRPI0607349A2 (pt) combinação de xolair com agente imunossupressor
GT200200114A (es) Champues con alcohol de behenilo
BRPI0510224A (pt) métodos de prevenção de doença autoimunológica e artigo industrializado

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.